SCHEMBL457033

SCHEMBL457033

COc1cccc(/C=C/C(=O)O)c1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.79
TRPM8 Q7Z2W7 1/20 0.68
KDM4E B2RXH2 1/20 0.66
CYP1A1 P04798 1/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2D6 P10635 1/20 0.63
ALOX5 P09917 1/20 0.63
MAOB P27338 2/20 0.60
GAA P10253 1/20 0.57
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
KMT2A Q03164 1/20 0.56
MAPT P10636 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PRMT1 Q99873 1/20 0.56
TFEB P19484 1/20 0.56
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
NTSR1 P30989 1/20 0.55
TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1056670 1.00 NFE2L2 (0.79) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
SCHEMBL6776487 1.00 NFE2L2 (0.79) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
2,6-Dimethoxybenzoic Acid SCHEMBL8133347 0.93 NFE2L2 (0.68) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
2,6-Dimethoxybenzoic Acid SCHEMBL8133343 0.93 NFE2L2 (0.68) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
SCHEMBL2744353 0.88 NFE2L2 (1.00) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
SCHEMBL2744350 0.88 NFE2L2 (1.00) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
SCHEMBL6844087 0.87 NFE2L2 (0.74) NFE2L2TRPM8CYP1A1CYP1A2CYP2D6
SCHEMBL6844089 0.87 NFE2L2 (0.74) NFE2L2TRPM8CYP1A1CYP1A2CYP2D6
SCHEMBL14950768 0.87 NFE2L2 (0.79) NFE2L2TRPM8KDM4ECYP1A1CYP1A2
SCHEMBL14691500 0.86 NFE2L2 (0.60) NFE2L2TRPM8KDM4ECYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-113024573-A Epodophyllotoxin derivative, preparation method and application thereof in preparation of antitumor drugs 江苏百奥信康医药科技有限公司 2021-06-25 CN claimed
EP-3307395-B1 SOLUBILISING AGENTS FOR UV SCREENING COMPOUNDS ISP INVESTMENTS LLC (US) 2020-08-05 EP claimed
EP-3600224-A1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP Investments LLC (US) 2020-02-05 EP claimed
WO-2018175836-A1 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2018-09-27 WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
CN-108181388-A A kind of method for differentiating willow type propolis and yang gum 中国农业科学院蜜蜂研究所 2018-06-19 CN claimed
EP-3310444-A1 WATER-IN-OIL SUNSCREEN COMPOSITION HAVING ORGANIC SUNSCREEN ACTIVES L'Oréal (FR) 2018-04-25 EP claimed
WO-2016204946-A1 WATER-IN-OIL SUNSCREEN COMPOSITION HAVING ORGANIC SUNSCREEN ACTIVES L'OREAL (FR) 2016-12-22 WO claimed
WO-2006108553-A1 METHOD OF MOLLUSC CONTROL SYNGENTA PARTICIPATIONS AG. (CH) 2006-10-19 WO claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-20060000778-A1 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2006-01-05 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-6451334-B2 PULSE ADMINISTERING OF A C1-C4 SUBSTITUTED AND/OR PHENYL SUBSTITUTED CARBOXYLIC ACID AND SALTS AND A CARRIER OR DILUENT TO STIMULATE CELLS IN TREATING BLOOD DISORDERS, E.G. SICKLE CELL ANEMIA, THALASSEMIA, BLOOD LOSS ETC. Perrine, Susan P. 2002-09-17 US claimed
WO-2002015691-A1 USE FOR CONIFER SAPLING PROTECTION AGAINST INSECT ATTACK ROBIGUS AB (SE) 2002-02-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS NFE2L2 4821/4885TRPM8 4585/4885KDM4E 2134/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 NFE2L2 1266/4885TRPM8 2210/4885KDM4E 1814/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 NFE2L2 3435/4885TRPM8 3148/4885KDM4E 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.